HKHS Intracranial Electrode Series

The HKHS Intracranial Electrode Series represents China’s leading portfolio of electrodes for epilepsy diagnosis and neurosurgical applications. Produced by Beijing Huake Hengsheng Medical Technology Co., Ltd. (HKHS), a wholly-owned subsidiary acquired by Sinovation in 2022, these electrodes have achieved domestic market leadership with annual sales reaching tens of thousands of units across over 200 Class A tertiary hospitals.

Product Overview

HKHS holds the distinction of being China’s first company to achieve commercialization of intracranial EEG signal acquisition consumables and the first domestic manufacturer to receive NMPA approval for these products. The company has grown to become the world’s third-largest intracranial electrode manufacturer, successfully achieving import substitution in this critical neurosurgical consumable category.

The electrode portfolio spans the complete range of intracranial EEG applications, from surface cortical recording to deep brain depth electrodes, thermocoagulation electrodes for lesion treatment, and specialized sphenoidal electrodes for temporal lobe evaluation. This broad offering enables epilepsy centers to source their complete electrode needs from a single domestic supplier.

Product Portfolio

Intracranial Depth Electrodes

Multi-contact depth electrodes designed for stereoelectroencephalography (SEEG) procedures. These electrodes record electrical activity from deep brain structures along their trajectory, enabling three-dimensional mapping of seizure networks. Available in various contact configurations and lengths to accommodate different implantation strategies.

Intracranial Cortical Electrodes

Grid and strip electrodes for subdural placement during cortical mapping procedures. These surface electrodes record from the brain surface to identify seizure onset zones and map eloquent cortex prior to resective surgery.

Depth Thermocoagulation Electrodes

Specialized electrodes enabling radiofrequency thermocoagulation of epileptogenic tissue identified during SEEG evaluation. This approach allows targeted lesioning of seizure onset zones without open surgery in select patients.

Sphenoidal Electrodes

Specialized electrodes for recording from mesial temporal structures via the foramen ovale approach. These semi-invasive electrodes provide enhanced access to temporal lobe activity compared to scalp electrodes without requiring craniotomy.

Key Features

Distributed to over 200 Class A tertiary hospitals, HKHS electrodes hold China’s leading market share in intracranial EEG consumables and rank third globally by manufacturer volume.

• Domestic Market Leadership: HKHS electrodes have achieved leading market share in China’s intracranial electrode segment, demonstrating clinical acceptance and reliability.

• Import Substitution: As the first Chinese company to commercialize these products, HKHS has successfully replaced imported electrodes across the domestic market.

• Full Portfolio: Complete range of electrode types enables single-source supply for epilepsy programs.

• Robot Compatibility: Designed for optimal performance with Sinovation’s neurosurgical robots, enabling integrated workflows from electrode implantation through monitoring.

• Quality Manufacturing: Production standards support annual volume in the tens of thousands of units.

Clinical Applications

SEEG Evaluation: Depth electrode implantation for thorough seizure network mapping in drug-resistant epilepsy. Multiple electrodes are placed stereotactically to record from suspected onset zones and propagation pathways.

Cortical Mapping: Grid and strip electrode placement for language, motor, and sensory mapping prior to epilepsy surgery in eloquent cortex regions.

Thermocoagulation Treatment: Following SEEG evaluation, depth thermocoagulation electrodes enable radiofrequency lesioning of identified seizure foci as a minimally invasive treatment option.

Temporal Lobe Evaluation: Sphenoidal electrodes provide enhanced mesial temporal recording for patients with suspected temporal lobe epilepsy when scalp EEG is insufficient.

The integration with Sinovation’s robotic platforms creates a synergistic workflow: robots provide precise electrode placement, HKHS electrodes provide high-quality signal acquisition, and subsequent analysis guides treatment decisions including potential LITT ablation.

Regulatory Status

Frequently Asked Questions

What is the relationship between HKHS and Sinovation?

Beijing Huake Hengsheng Medical Technology Co., Ltd. (HKHS) was acquired by Sinovation in 2022 and operates as a wholly-owned subsidiary. The acquisition expanded Sinovation’s product portfolio from equipment into neurosurgical consumables.

What market position does HKHS hold?

HKHS is China’s domestic market leader in intracranial electrodes and the world’s third-largest manufacturer. The company was China’s first to commercialize intracranial EEG electrodes and has achieved substantial import substitution.

How do HKHS electrodes integrate with Sinovation robots?

Sinovation’s neurosurgical robots (Sinobot X1, Q300, X1000) provide precise stereotactic placement of HKHS depth electrodes. This integrated workflow ensures optimal electrode positioning for SEEG evaluation.

What types of electrodes does HKHS manufacture?

The portfolio includes depth electrodes for SEEG, cortical grid and strip electrodes for subdural mapping, thermocoagulation electrodes for RF ablation, and sphenoidal electrodes for temporal lobe evaluation.